| 62.92 4.6 (7.89%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 77.73 | 1-year : | 90.78 |
| Resists | First : | 66.55 | Second : | 77.73 |
| Pivot price | 58.78 |
|||
| Supports | First : | 44.27 |
Second : | 30.51 |
| MAs | MA(5) : | 59.7 |
MA(20) : | 55.69 |
| MA(100) : | 36.68 |
MA(250) : | 28.81 |
|
| MACD | MACD : | 5.8  |
Signal : | 6.1 |
| %K %D | K(14,3) : | 68.5 |
D(3) : | 66.3 |
| RSI | RSI(14): 67.6 |
|||
| 52-week | High : | 66.55 | Low : | 9.63 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MBX ] has closed below upper band by 20.9%. Bollinger Bands are 18.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 63.14 - 63.59 | 63.59 - 63.94 |
| Low: | 54.67 - 55.09 | 55.09 - 55.42 |
| Close: | 62.3 - 63.03 | 63.03 - 63.6 |
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
Mon, 13 Jul 2026
MBX Biosciences Appoints New CEO and CFO: Leadership Changes Announced in July 2026 8-K Filing - Minichart
Mon, 13 Jul 2026
MBX Biosciences (Nasdaq: MBX) names new CEO and CFO, sets pay and equity - Stock Titan
Wed, 08 Jul 2026
FMR LLC discloses 11.2% ownership in MBX Biosciences (MBX) amendment - Stock Titan
Thu, 25 Jun 2026
MBX Biosciences, Inc. Actuals & Estimates (NASDAQ:MBX) - TradingView
Thu, 25 Jun 2026
MBX Forecast — Price Target — Prediction for 2027 - TradingView
Fri, 15 May 2026
Insider Stock Buying Reaches US$1.06m On MBX Biosciences - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 120.5 (%) |
| Shares Short | 5,900 (K) |
| Shares Short P.Month | 4,810 (K) |
| EPS | -2.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.19 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.7 % |
| Return on Equity (ttm) | -25.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -77 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -31.31 |
| PEG Ratio | 0 |
| Price to Book value | 6.83 |
| Price to Sales | 0 |
| Price to Cash Flow | -38.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|